Lantus

RSS

insulin glargine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Lantus. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lantus.

This EPAR was last updated on 01/12/2021

Authorisation details

Product details
Name
Lantus
Agency product number
EMEA/H/C/000284
Active substance
insulin glargine
International non-proprietary name (INN) or common name
insulin glargine
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AE04
Publication details
Marketing-authorisation holder
sanofi-aventis Deutschland GmbH
Revision
37
Date of issue of marketing authorisation valid throughout the European Union
09/06/2000
Contact address
Industriepark Höchst
D-65926 Frankfurt am Main
Germany

Product information

24/11/2021 Lantus - EMEA/H/C/000284 - IA/0125

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children aged two years and above

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating
2 ratings